SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* BVCF Management, Ltd. (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT (Street) SHANGHAI F4 200023 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Jaguar Animal Health, Inc. [ JAGX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/18/2015
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2015		C		1,483,326	A	(1)	1,522,881	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	05/18/2015		C(1)			2,224,991	(1)	(1)	Common Stock	1,483,326	$0	0	I	By Kunlun Pharmaceuticals, Ltd.(2)

1. Name and Address of Reporting Person* BVCF Management, Ltd. (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT (Street) SHANGHAI F4 200023 (City) (State) (Zip)

1. Name and Address of Reporting Person* Kunlun Pharmaceuticals, Ltd. (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT (Street) SHANGHAI F4 200023 (City) (State) (Zip)

1. Name and Address of Reporting Person* BVCF III, L.P. (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT (Street) SHANGHAI F4 200023 (City) (State) (Zip)

1. Name and Address of Reporting Person* BVCF III-A, L.P. (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT (Street) SHANGHAI F4 200023 (City) (State) (Zip)

Explanation of Responses:

1. These securities automatically converted into Issuer's common stock on a 1.5 to 1 basis immediately prior to the consummation of Issuer's initial public offering ("IPO") and had no expiration date.

2. Represents (i) 39,555 shares held by Sichuan Biopharma ("Sichuan") and (ii) 1,488,326 shares held by Kunlun Pharmaceuticals, Ltd. ("Kunlun"). Sichuan is an investment vehicle of BVCF Management, Ltd. ("BVCF"). Kunlun is directly owned by BVCF III, L.P. and BVCF III-A, L.P. BVCF III, L.P. and BVCF III-A, L.P. are managed by BVCF. Zhi Yang is Chairman, Founder, Managing Partner and sole shareholder of BVCF and may be deemed to have sole voting and dispositive power with respect to the shares held by Sichuan and Kunlun. Zhi Yang disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

	/s/ John A. Kallassy, Attorney-in-Fact for BVCF Management, Ltd.	05/18/2015
	/s/ John A. Kallassy, Attorney-in-Fact for Kunlun Pharmaceuticals, Ltd.	05/18/2015
	/s/ John A. Kallassy, Attorney-in-Fact for BVCF III, L.P.	05/18/2015
	/s/ John A. Kallassy, Attorney-in-Fact for BVCF III-A, L.P.	05/18/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.